{
  "name": "Amgen",
  "slug": "amgen",
  "ticker": "AMGN",
  "fetched_at": "2025-10-23T12:23:44.907124+00:00",
  "news": [
    {
      "title": "Drug With a 30-Year Monopoly Is Target of State-Level Push to Curb Prices - The New York Times",
      "link": "https://news.google.com/rss/articles/CBMikwFBVV95cUxPOGtMT0RzU0RhVGtHcjRGc1ZveDNZOUJLMGh3eVB2S3Eyb21tSUpmczRHUEtmWUYtdnlXVGNFUHN6RUVNa3BtZGNGcG1zVEJaZEZUdi03R2R4VHVENzBxcjhrektwRTNFOWpOSTZuSzFpbkRWZktQeDROQkdiV0RCcnBpRFljTDRXSkhWbklkZFhNLW8?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMikwFBVV95cUxPOGtMT0RzU0RhVGtHcjRGc1ZveDNZOUJLMGh3eVB2S3Eyb21tSUpmczRHUEtmWUYtdnlXVGNFUHN6RUVNa3BtZGNGcG1zVEJaZEZUdi03R2R4VHVENzBxcjhrektwRTNFOWpOSTZuSzFpbkRWZktQeDROQkdiV0RCcnBpRFljTDRXSkhWbklkZFhNLW8?oc=5\" target=\"_blank\">Drug With a 30-Year Monopoly Is Target of State-Level Push to Curb Prices</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">The New York Times</font>",
      "published": "2025-10-23T09:00:45+00:00",
      "source": "The New York Times"
    },
    {
      "title": "With questions surrounding its gastric cancer drug, Amgen fills in some gaps - statnews.com",
      "link": "https://news.google.com/rss/articles/CBMie0FVX3lxTE1zNDBYYlJHWGU3TktJb1dpeUI0MkUxZFBpQklTbW1YT3BWWGw4RjVNSm5BOFBZTUJDamRmNUg3bVJaOHhqV21QZXF0MzdBOU14V1JVZVhseWNaSTI4M2NGa0xkbUJLVHhvel9SWDhYd251Y3l3aFAzZkZndw?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMie0FVX3lxTE1zNDBYYlJHWGU3TktJb1dpeUI0MkUxZFBpQklTbW1YT3BWWGw4RjVNSm5BOFBZTUJDamRmNUg3bVJaOHhqV21QZXF0MzdBOU14V1JVZVhseWNaSTI4M2NGa0xkbUJLVHhvel9SWDhYd251Y3l3aFAzZkZndw?oc=5\" target=\"_blank\">With questions surrounding its gastric cancer drug, Amgen fills in some gaps</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">statnews.com</font>",
      "published": "2025-10-20T14:52:07+00:00",
      "source": "statnews.com"
    },
    {
      "title": "AstraZeneca, Amgen’s Tezspire approved in EU as add-on therapy - TipRanks",
      "link": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxNUXRYaFdsZ0gxN1JlN002ME54LU1TN1hEa29qdnlramc4bm1DVlVpUUdpQlVFb2RWeGs1c3o3LWoyakhuZVFVMlVTRS1fSGF0Snl4RWFpRm1NWXBsdWZDUHdaSUNZZFhVM2hKanJoZklSX0V4S0xMQWJRY25pMkxnLTFuM2VEV3JELUV2NnRTTEw3bkdwWVRaRzlXQlFQdmkyTS1CTDdzeWU?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMiqAFBVV95cUxNUXRYaFdsZ0gxN1JlN002ME54LU1TN1hEa29qdnlramc4bm1DVlVpUUdpQlVFb2RWeGs1c3o3LWoyakhuZVFVMlVTRS1fSGF0Snl4RWFpRm1NWXBsdWZDUHdaSUNZZFhVM2hKanJoZklSX0V4S0xMQWJRY25pMkxnLTFuM2VEV3JELUV2NnRTTEw3bkdwWVRaRzlXQlFQdmkyTS1CTDdzeWU?oc=5\" target=\"_blank\">AstraZeneca, Amgen’s Tezspire approved in EU as add-on therapy</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">TipRanks</font>",
      "published": "2025-10-22T11:18:17+00:00",
      "source": "TipRanks"
    },
    {
      "title": "Amgen, AZ's Tezspire challenges Dupixent in nasal polyps - pharmaphorum",
      "link": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxQMXJyVENicDc3NS1Nd2tCSFdneU04am5uendhY2ZybzBiM0IzNDVSX19pbXR4R3ZoQ2RHVG1ZaGM0cjFtM0Fndmg3MXhieEFSQ3l5eTFoalJYOW5OT3dOT25DNVo0RUxpbmpRbmhYY1RRc0hfOHNmbk5FVEZKM09ueUQxdDJRbFV4?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMiiAFBVV95cUxQMXJyVENicDc3NS1Nd2tCSFdneU04am5uendhY2ZybzBiM0IzNDVSX19pbXR4R3ZoQ2RHVG1ZaGM0cjFtM0Fndmg3MXhieEFSQ3l5eTFoalJYOW5OT3dOT25DNVo0RUxpbmpRbmhYY1RRc0hfOHNmbk5FVEZKM09ueUQxdDJRbFV4?oc=5\" target=\"_blank\">Amgen, AZ's Tezspire challenges Dupixent in nasal polyps</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">pharmaphorum</font>",
      "published": "2025-10-20T10:02:49+00:00",
      "source": "pharmaphorum"
    },
    {
      "title": "Hiring and drug review slowdown at the FDA - statnews.com",
      "link": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxPaUF1TUVVY3BHR3VyMlJEcEFxUUFHMHVMQmtKNWVCMFplSU0zSzhZZHRyVnozSl9aTFkwUVg5MUM2ZUF0NWZaVHdMTWJRWHFaWmFSWG5IRUltUVNvcE9PQm5zSm9ESThpMm5mVy1fbTFVVjBkeDJyNlRwSnMyWjA4blQyOVhEVDI0?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMiiAFBVV95cUxPaUF1TUVVY3BHR3VyMlJEcEFxUUFHMHVMQmtKNWVCMFplSU0zSzhZZHRyVnozSl9aTFkwUVg5MUM2ZUF0NWZaVHdMTWJRWHFaWmFSWG5IRUltUVNvcE9PQm5zSm9ESThpMm5mVy1fbTFVVjBkeDJyNlRwSnMyWjA4blQyOVhEVDI0?oc=5\" target=\"_blank\">Hiring and drug review slowdown at the FDA</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">statnews.com</font>",
      "published": "2025-10-21T14:22:42+00:00",
      "source": "statnews.com"
    },
    {
      "title": "Amgen to sell cholesterol drug at 60% discount to cash-paying US patients - Reuters",
      "link": "https://news.google.com/rss/articles/CBMiywFBVV95cUxQY093WGV4Y3o1SmQ5TElWbXNtbUxhYUgyLTNNXzdnTUM4dEphOVZ1ZkNieUNlbGx0SmtNbzRpaWVRY1VnVFpld2RVMU5Xc0E1WjJ6RlVCeDkwQ25kOVlMekI5MGlNaW5UZUN0dVdKWWFfQ0ExMjJIUEIwakxQckd1eFc4YzROWUxwZ1h6T0RsdXFGTXNIQTdXSk1FWUwxOVZkTkdmdW53TlRZdGZMRDE1eHB1MVNoZzMzUExrQ1UxRTJGRGw1dF84V200VQ?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMiywFBVV95cUxQY093WGV4Y3o1SmQ5TElWbXNtbUxhYUgyLTNNXzdnTUM4dEphOVZ1ZkNieUNlbGx0SmtNbzRpaWVRY1VnVFpld2RVMU5Xc0E1WjJ6RlVCeDkwQ25kOVlMekI5MGlNaW5UZUN0dVdKWWFfQ0ExMjJIUEIwakxQckd1eFc4YzROWUxwZ1h6T0RsdXFGTXNIQTdXSk1FWUwxOVZkTkdmdW53TlRZdGZMRDE1eHB1MVNoZzMzUExrQ1UxRTJGRGw1dF84V200VQ?oc=5\" target=\"_blank\">Amgen to sell cholesterol drug at 60% discount to cash-paying US patients</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Reuters</font>",
      "published": "2025-10-06T07:00:00+00:00",
      "source": "Reuters"
    },
    {
      "title": "AMGEN ANNOUNCES $650M EXPANSION OF U.S. MANUFACTURING, CREATING HUNDREDS OF NEW JOBS - PR Newswire",
      "link": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxOVC03UXRKQ3Q4OTFzYjh5bUV6WWRRRHVOU2pqcDY1MGhUbm1PQnZCTEpQYzZhcFlsN2pDSHZTU0xib0JuVVhuTlBMMVVuRGhtX1F0clBxVHM2Z2lUR1VRSkItM3VvVGh6R0NPMWhaTkRZRGVOVlFhNzdGUkZ5UWpzRk4zU2xIdkdRMkFrRl83UjB2LXFjMWdRUXh1aUs3WG94SXI5NWJqVVEyYzFSZVY5TERfZGlJOC1DbVM4RnNBbFJOVW9GbW9PQ1NydXBsdHdtTkE?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMi0gFBVV95cUxOVC03UXRKQ3Q4OTFzYjh5bUV6WWRRRHVOU2pqcDY1MGhUbm1PQnZCTEpQYzZhcFlsN2pDSHZTU0xib0JuVVhuTlBMMVVuRGhtX1F0clBxVHM2Z2lUR1VRSkItM3VvVGh6R0NPMWhaTkRZRGVOVlFhNzdGUkZ5UWpzRk4zU2xIdkdRMkFrRl83UjB2LXFjMWdRUXh1aUs3WG94SXI5NWJqVVEyYzFSZVY5TERfZGlJOC1DbVM4RnNBbFJOVW9GbW9PQ1NydXBsdHdtTkE?oc=5\" target=\"_blank\">AMGEN ANNOUNCES $650M EXPANSION OF U.S. MANUFACTURING, CREATING HUNDREDS OF NEW JOBS</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">PR Newswire</font>",
      "published": "2025-09-26T07:00:00+00:00",
      "source": "PR Newswire"
    },
    {
      "title": "Exencial Wealth Advisors LLC Decreases Position in Amgen Inc. $AMGN - MarketBeat",
      "link": "https://news.google.com/rss/articles/CBMixAFBVV95cUxNZGVuY3FzcFIzTm4zb2F6NnJzQWo2M2NJbTJmRE9lLTJpTHR4Sl9EZ2JmNFZDMTViYWJVMUZBMXljMi14MG1lMTl6Mk8zTTNhSWVNcUlyajNlUkx4VHNoOURUdkVxRTlKRjJkYVRKbFhhTUpOaGZFT3hwRENMMWNxZjNDZEdMYTJCSzBjQzR0U21XcENrZGNVNjFWMzNuaUNvbk12cVRYSVU0NnFSWlVKZzlGZFVqYWduR3JjOUl6bUV0dkxW?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMixAFBVV95cUxNZGVuY3FzcFIzTm4zb2F6NnJzQWo2M2NJbTJmRE9lLTJpTHR4Sl9EZ2JmNFZDMTViYWJVMUZBMXljMi14MG1lMTl6Mk8zTTNhSWVNcUlyajNlUkx4VHNoOURUdkVxRTlKRjJkYVRKbFhhTUpOaGZFT3hwRENMMWNxZjNDZEdMYTJCSzBjQzR0U21XcENrZGNVNjFWMzNuaUNvbk12cVRYSVU0NnFSWlVKZzlGZFVqYWduR3JjOUl6bUV0dkxW?oc=5\" target=\"_blank\">Exencial Wealth Advisors LLC Decreases Position in Amgen Inc. $AMGN</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">MarketBeat</font>",
      "published": "2025-10-23T10:45:16+00:00",
      "source": "MarketBeat"
    }
  ],
  "product_launches": [
    {
      "title": "A Look at Amgen’s (AMGN) Valuation as Repatha Scores Major Trial Win and Direct Sales Launch Spurs Optimism - Yahoo Finance",
      "link": "https://news.google.com/rss/articles/CBMihgFBVV95cUxObWpGcHFxUm1WbnhhdFJUOW1kcjlGamhOQTdxdnVqWVRmQkxzNzdYd0poQk96QVByUENRMHhxQlFhVXctWGhjSWw4bjIzMXoxdFhLaVhpU0xMbnltTjhBejY4X1lQOWJuRENDNjVTbWxRRjZMMERRT0RVLVdETjhUcVljeTM3QQ?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMihgFBVV95cUxObWpGcHFxUm1WbnhhdFJUOW1kcjlGamhOQTdxdnVqWVRmQkxzNzdYd0poQk96QVByUENRMHhxQlFhVXctWGhjSWw4bjIzMXoxdFhLaVhpU0xMbnltTjhBejY4X1lQOWJuRENDNjVTbWxRRjZMMERRT0RVLVdETjhUcVljeTM3QQ?oc=5\" target=\"_blank\">A Look at Amgen’s (AMGN) Valuation as Repatha Scores Major Trial Win and Direct Sales Launch Spurs Optimism</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Yahoo Finance</font>",
      "published": "2025-10-16T17:18:39+00:00",
      "source": "Yahoo Finance"
    },
    {
      "title": "$239/month for Repatha — AmgenNow direct-to-patient program offers nearly 60% discount in U.S. - Stock Titan",
      "link": "https://news.google.com/rss/articles/CBMivgFBVV95cUxNX1VmYlB3RmtYTG5rd1dJblFhNVh6UEFHdzkxTm9VRy0wMVc1SDNuZ0JLYUNRTHA0VVhBOEpWb1RUa2FONTVMY19CSTJSVVJSUjFwbkIwMFdtalFEWHRmQTVvQnFzY3YxYUFqaDc2cjBydnV0RjdSWGhCTzdaWDl1Y2VNVU9LdzZvLW1FZHhnam12Qm1XaEg0M3ZEeTh4aHNkcUZsazNRa0tuTGY3WXNiZjZKSnh2SkJRVVl6OXRR?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMivgFBVV95cUxNX1VmYlB3RmtYTG5rd1dJblFhNVh6UEFHdzkxTm9VRy0wMVc1SDNuZ0JLYUNRTHA0VVhBOEpWb1RUa2FONTVMY19CSTJSVVJSUjFwbkIwMFdtalFEWHRmQTVvQnFzY3YxYUFqaDc2cjBydnV0RjdSWGhCTzdaWDl1Y2VNVU9LdzZvLW1FZHhnam12Qm1XaEg0M3ZEeTh4aHNkcUZsazNRa0tuTGY3WXNiZjZKSnh2SkJRVVl6OXRR?oc=5\" target=\"_blank\">$239/month for Repatha — AmgenNow direct-to-patient program offers nearly 60% discount in U.S.</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Stock Titan</font>",
      "published": "2025-10-06T07:00:00+00:00",
      "source": "Stock Titan"
    },
    {
      "title": "Amgen, Kyowa Kirin Bolster Safety Profile for Atopic Dermatitis Hopeful - BioSpace",
      "link": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQVEJYNkQ0cURCVTNSd1VIbU1JLWtmblBqXzNDZnp6SVBBcWpGcm5zNWdaUFZwdjN4aGR4TnJoYm9PMWk2STRNdmdKMjRKU2pQVURtamRpUDBja3ZhYk1ONHJRemdtdkpVRHJ3SXBESkdyNG1hMW1ZQW4wb0xpYmMxY0E5RkRyVERkaS1FczJlUmZmbVZRN2VWenB5czdkeFg4eG5jNkZqQm9RU3FaMjl6dl9R?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMisgFBVV95cUxQVEJYNkQ0cURCVTNSd1VIbU1JLWtmblBqXzNDZnp6SVBBcWpGcm5zNWdaUFZwdjN4aGR4TnJoYm9PMWk2STRNdmdKMjRKU2pQVURtamRpUDBja3ZhYk1ONHJRemdtdkpVRHJ3SXBESkdyNG1hMW1ZQW4wb0xpYmMxY0E5RkRyVERkaS1FczJlUmZmbVZRN2VWenB5czdkeFg4eG5jNkZqQm9RU3FaMjl6dl9R?oc=5\" target=\"_blank\">Amgen, Kyowa Kirin Bolster Safety Profile for Atopic Dermatitis Hopeful</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">BioSpace</font>",
      "published": "2025-09-10T07:00:00+00:00",
      "source": "BioSpace"
    },
    {
      "title": "Amgen settles Prolia patent suit with Celltrion, teeing up potential biosimilar launch in June - Fierce Pharma",
      "link": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxONkt3YUVEeUpwTU5LYVgtaTk2THhoMEt3ZUliWC1sWmhTTGR4M0hwaVpFMEFla01mUTdxbGVueWNGVThVT3U1T3R2NTQwaEkxeEI5MjRPMzVQUlhaU3hKNVVqQmFFY3BMQ2c3enphdTVLVy1Wb3dTb0l4Rnk3czFVTVFZbUdvVVJwa1I4Z3FDOFByVDZIV21Ccnk5VTd5U3VtNHhuVDdQUldHNm81YnZ6MHFReDBJNmk1S3BucTJhUlplcnc?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMiwwFBVV95cUxONkt3YUVEeUpwTU5LYVgtaTk2THhoMEt3ZUliWC1sWmhTTGR4M0hwaVpFMEFla01mUTdxbGVueWNGVThVT3U1T3R2NTQwaEkxeEI5MjRPMzVQUlhaU3hKNVVqQmFFY3BMQ2c3enphdTVLVy1Wb3dTb0l4Rnk3czFVTVFZbUdvVVJwa1I4Z3FDOFByVDZIV21Ccnk5VTd5U3VtNHhuVDdQUldHNm81YnZ6MHFReDBJNmk1S3BucTJhUlplcnc?oc=5\" target=\"_blank\">Amgen settles Prolia patent suit with Celltrion, teeing up potential biosimilar launch in June</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Fierce Pharma</font>",
      "published": "2025-01-28T08:00:00+00:00",
      "source": "Fierce Pharma"
    },
    {
      "title": "Amgen: Biosimilars And Rare Disease Pipeline Crucial To Overcome Patent Cliff Concerns - Seeking Alpha",
      "link": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNNldFcDdyVUNrRFhsN2JMUDZuakRJNDN5R0JBNzFfbXNuaGVLVTRubVhsV3l2eEk4MGR2X2xLcXVON3NHVVZOVjZvZHNzdHBsTGVNZEFJaEp2WGRxUnNYdng4TS1yaWNrd1g5bW5tcnNvZUh1QzlleW96akRZUG1tNGRKLXdqdmg5TUdudlpielVzcHd2VUpYa3pfWkJjX0lESEJDc3BET1hFWGtreWdqNEdkNlMtT2dncThfMVVuOA?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMivwFBVV95cUxNNldFcDdyVUNrRFhsN2JMUDZuakRJNDN5R0JBNzFfbXNuaGVLVTRubVhsV3l2eEk4MGR2X2xLcXVON3NHVVZOVjZvZHNzdHBsTGVNZEFJaEp2WGRxUnNYdng4TS1yaWNrd1g5bW5tcnNvZUh1QzlleW96akRZUG1tNGRKLXdqdmg5TUdudlpielVzcHd2VUpYa3pfWkJjX0lESEJDc3BET1hFWGtreWdqNEdkNlMtT2dncThfMVVuOA?oc=5\" target=\"_blank\">Amgen: Biosimilars And Rare Disease Pipeline Crucial To Overcome Patent Cliff Concerns</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Seeking Alpha</font>",
      "published": "2025-07-15T07:00:00+00:00",
      "source": "Seeking Alpha"
    }
  ],
  "stock": {
    "ticker": "AMGN",
    "currency": "USD",
    "latest": {
      "date": "2025-10-22",
      "close": 295.9800109863281
    },
    "history": [
      {
        "date": "2025-10-14",
        "close": 293.8500061035156
      },
      {
        "date": "2025-10-15",
        "close": 297.32000732421875
      },
      {
        "date": "2025-10-16",
        "close": 295.80999755859375
      },
      {
        "date": "2025-10-17",
        "close": 298.80999755859375
      },
      {
        "date": "2025-10-20",
        "close": 303.3299865722656
      },
      {
        "date": "2025-10-21",
        "close": 301.1400146484375
      },
      {
        "date": "2025-10-22",
        "close": 295.9800109863281
      }
    ],
    "name": "Amgen Inc."
  }
}